UNITE-VT

• Research type

  Research Study

• Full title

  Using Non-Invasive mapping To Eliminate structural heart disease Ventricular Tachycardia: a UK Randomised Controlled Trial

• IRAS ID

  366199

• Contact name

  Tarvinder Dhanjal

• Contact email

  tarvinder.dhanjal@warwick.ac.uk

• Sponsor organisation

  University of Warwick

• Duration of Study in the UK

  1 years, 11 months, 29 days

• Research summary

  Ventricular tachycardia (VT) is an abnormal and dangerous heart rhythm affecting the lower chambers of the heart (the ventricles). Patients with structural heart disease caused by previous heart attacks are at an increased risk of developing VT. Current guidelines recommend that patients who develop this abnormal heart rhythm are considered for invasive catheter ablation (ICA). This is an invasive procedure where specialised catheters and a 3D electro-anatomical mapping (EAM) system are used to identify the region of the heart responsible for the VT, which is then treated by tissue heating or freezing (ablation). Although significant improvements have been made in both mapping and ablation technologies, these procedures remain technically challenging and time consuming.
  View into ventricular onset (VIVO, Catheter Precision) is a non-invasive, mapping system already being used within the NHS. It uses images from previous heart scans, a picture of the patient’s chest (taken at the start of the procedure) and a 12-lead electrocardiogram (ECG) tracing, to locate where the VT is coming from. The VIVO map can therefore highlight the likely region of interest for ICA prior to invasive EAM.
  This study will be a prospective, multi-centre, two-arm, non-blinded, randomised controlled trial (RCT). Patients will be evenly randomised (50:50) into a standard VT ablation group and a VIVO guided ablation group. In the VIVO guided ablation group, invasive EAM will be restricted to the region of interest identified using the VIVO map, rather than whole chamber mapping required for standard ablation. The primary objective will be to determine if the VIVO non-invasive mapping system reduces procedure duration and therefore improves workflow efficiency. Secondary objectives will assess the procedural success, safety and patient perceived health benefits of a VIVO guided ablation versus standard ablation.

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  26/YH/0045

• Date of REC Opinion

  8 Apr 2026

• REC opinion

  Further Information Favourable Opinion